

ChemComm

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

COMMUNICATION

Complete switch from α 2,3- to α 2,6-regioselectivity in *Pasteurella dagmatis* β -D-galactoside sialyltransferase by active-site redesign

Cite this: DOI: 10.1039/x0xx00000x

Katharina Schmölzer,^a Tibor Czabany,^b Christiane Luley-Goedl,^a Tea Pavkov-Keller,^a Doris Ribitsch,^a Helmut Schwab,^c Karl Gruber,^d Hansjörg Weber^e and Bernd Nidetzky^{*ab}

Received 00th December 2014,
Accepted 00th January 2012


DOI: 10.1039/x0xx00000x

www.rsc.org/

Structure-guided active-site redesign of a family GT-80 β -D-galactoside sialyltransferase (from *Pasteurella dagmatis*) to change enzyme regioselectivity from α 2,3 in wild type to α 2,6 in a P7H-M117A double mutant is reported. Biochemical data for sialylation of lactose together with protein crystal structures demonstrate highly precise enzyme engineering.

α 2,3- and α 2,6-sialic acid capped oligosaccharides are highly important in human glycobiology.¹ Sialylated human milk oligosaccharides (HMOs) are of interest due to their roles in the development and health protection of newborn infants.² Nearly 20% of the total HMOs comprise sialic acid,² and sialyllactose is one of their main components,³ with both regioisomers being biologically active.⁴ Sialylated HMOs contain *N*-acetylneuraminic acid (Neu5Ac) attached to D-galactosyl (Scheme 1) or *N*-acetyl-D-glucosaminyl residues through α 2,3- or α 2,6-linkage.²⁻³ Since natural availability of sialylated HMOs is limited, synthetic sialyloligosaccharides (e.g. sialyllactose) are demanded as infant formula^{2,5} and nutraceutical ingredients.⁴

Stereo- and regiocontrol are problems requiring special attention when installing a sialyl group on a nascent oligosaccharide.⁶ Selective biocatalytic sialylation avoids use of protecting group chemistry and therefore presents a highly attractive route for sialylated HMO synthesis.⁷ Sialyltransferases (STs; EC 2.4.99) catalyze transfer of a Neu5Ac residue from CMP-Neu5Ac to an acceptor oligosaccharide. Complementarily regioselective STs from bacterial,⁸ mammalian^{8i,8j,9} and viral¹⁰ sources, were successfully applied for enzymatic α 2,3- and α 2,6-sialylation of various acceptor substrates. Sialyllactose and sialyl-(poly)-*N*-acetylglucosamine derivatives were produced in gram quantities.^{8h-j,11} Engineered STs exhibiting tailored selectivities could be of interest for flexible sialoside synthesis.



Scheme 1 Enzymatic synthesis of α 2,3- and α 2,6-sialyl-HMOs by sialyltransferases with CMP-Neu5Ac and β -D-galactoside substrates.

Hitherto unprecedented switch in ST regioselectivity from α 2,3 in wild type to α 2,6 in a designed enzyme variant is reported. High-resolution protein structures show the active-site remodeling of the parent ST to have been precise at the atomic level. Results provide deepened insights into determinants of ST selectivity. They are also relevant for practical synthesis: a pair of "ST twins" is created that differ in regioselectivity, but otherwise have uniform synthesis conditions and substrate preferences. We show their application to alternative 3'- or 6'-sialylation of lactose and *N*-acetylglucosamine.

Glycosyltransferase family GT-80 comprises α 2,3-, α 2,6- and also mixed α 2,3/ α 2,6-selective STs.^{8b,8d,8e,12} These STs are furthermore characterized by high specific activity and broad acceptor substrate scope, which typically includes lactose.^{8b,8d,8e,12} Redesign of the naturally α 2,3-selective β -D-galactoside ST from *Pasteurella dagmatis* (PdST)^{12a} was developed from two family GT-80 protein structures that delineate distinct lactose binding modes in the α 2,3/ α 2,6-selective ST from *Pasteurella multocida* (PmST1)¹³ and the α 2,6-selective ST from *Photobacterium sp.* JT-ISH-224¹⁴ (Fig. 1). PdST is 70% identical in amino acid sequence to PmST1, and residues of their acceptor binding sites (Fig. 1a) are completely identical. Different orientations of the lactose's β -D-galactosyl




Fig. 1 Acceptor-binding site comparison of family GT-80 $\alpha 2,3$ - and $\alpha 2,6$ -sialyltransferases. (a) $\alpha 2,3/\alpha 2,6$ -sialyltransferase from *P. multocida* PmST1 (PDB code 2ILV)¹³. (b) $\alpha 2,6$ -sialyltransferase from *Photobacterium* sp. JT-ISH-224 (PDB code 2Z4T)¹⁴.

moiety relative to the proposed catalytic base of the enzyme (Asp¹⁴¹, Asp²³²),¹³⁻¹⁵ such that either the 3-OH (Fig. 1a) or the 6-OH (Fig. 1b) is brought into a reactive position, appeared to have been evoked by a two amino acid residue substitution where Pro³⁴ and Met¹⁴⁴ in PmST1 are exchanged to, respectively, His¹²³ and Ala²³⁵ in *Photobacterium* ST. Family-wide sequence comparison of GT-80 STs revealed clear sub-categorization of β -galactoside $\alpha 2,3$ - and $\alpha 2,6$ -STs according to a conserved Pro/Met or His/Ala(Ser) sequence pattern (see Table S1 in ESI†) that was therefore hypothesized to be decisive for $\alpha 2,3$ compared to $\alpha 2,6$ ST regioselectivity. Note, however, that a group of $\alpha 2,3$ -selective STs within family GT-80 that are flexible in using α/β -galactosides for sialylation also possess an Ala instead of a Met (Table S1 in ESI†). To graft $\alpha 2,6$ -selective ST activity on PdST, the relevant residues Pro⁷ and Met¹¹⁷ were replaced to generate P7H and P7H-M117A variants of the naturally $\alpha 2,3$ -selective wild-type enzyme.

Purified preparations of wild type and variant PdST were obtained from *Escherichia coli* overexpression culture producing target protein equipped with a C-terminal His₆-tag for purification by metal chelate chromatography. Specific activity for sialyltransfer to lactose (1 mM) from CMP-Neu5Ac (1 mM) was determined at pH 8.0, measuring the consumption of CMP-Neu5Ac and the release of CMP by HPLC, and the formation of sialyllactose by HPAEC-PAD (high-performance anion exchange chromatography with pulsed amperometric detection). The specific activity of P7H mutant was identical (5.8 U mg⁻¹) to that of the wild-type enzyme. The specific activity of the P7H-M117A double mutant was lowered somewhat in comparison (2.2 U mg⁻¹). Sialyllactose regioisomers formed in the different enzymatic reactions were identified from their elution in HPAEC-PAD referenced against authentic standards of 3'- and 6'-sialyllactose, as shown in Fig. 2. The wild-type enzyme produced 3'-




Fig 2 HPAEC-PAD analysis showing gradual change from $\alpha 2,3$ - to $\alpha 2,6$ -regioselective sialyltransfer to lactose, resulting from substitution of Pro⁷ by His and from additional substitution of Met¹¹⁷ by Ala in PdST. First 5 min are omitted for clarity (see Fig. S1 in ESI†). Note that the identity of the sialyllactose products formed was additionally confirmed by NMR.

sialyllactose exclusively. Single mutation of Pro⁷ to His resulted in drastic change of enzyme regioselectivity, so that 6'-sialylation of lactose was now strongly favored by the enzyme. However, 3'-sialyllactose was still present to ~4% of total transfer product (Fig. 2), showing that $\alpha 2,3$ -ST activity had not been completely abolished in the P7H mutant. The double mutant P7H-M117A, by contrast, featured complete $\alpha 2,3$ to $\alpha 2,6$ switch in ST regioselectivity. No 3'-sialyllactose was detectable ($\leq 1\%$) next to 6'-sialyllactose as product of the enzymatic sialyltransfer (Fig. 2). Therefore, these results suggested distinct and divergingly important roles for His and Ala in conferring $\alpha 2,6$ -regioselectivity to STs of family GT-80. While the His was clearly essential, the Ala seemed to fulfil an auxiliary function in fine-tuning of enzyme selectivity. Consistent with this notion, the M117A mutant of PdST did not exhibit significant change in regioselectivity as compared to the wild-type enzyme (Table 1). Evidence from enzyme kinetic characterization (Table 1) supports the idea that in terms of catalytic efficiency (k_{cat}/K_m) and also turnover frequency (k_{cat}), the replacement Pro \rightarrow His is tolerated much better by the enzyme than the Met \rightarrow Ala replacement. Interestingly, Pro \rightarrow His replacement in M117A variant resulted in clear recovery of activity parameters that had been decreased in the single-site variant as compared to wild-type PdST.

Table 1 Activity and selectivity parameters of wild-type PdST and site-directed variants thereof.

	WT	M117A	P7H	P7H-M117A
Regioselectivity	$\alpha 2,3$	$\alpha 2,3^a$	$\alpha 2,6^b$	$\alpha 2,6$
Specific activity [U mg ⁻¹]	5.7	0.70	5.8	2.2
K_m [mM]	1.5	15	3.8	6.4
k_{cat} [s ⁻¹]	24	11	16	18
k_{cat}/K_m [s ⁻¹ mM ⁻¹]	16	0.74 ^c	4.3	2.8

^a 4% of 6'-sialyllactose and ^b 4% of 3'-sialyllactose were detected. Apparent kinetic parameters for lactose as sialyltransferase acceptor substrate. Kinetic parameters have S.D. of $\leq 10\%$, except ^c 20%. Measurements were done using CMP-Neu5Ac (10 mM) and a varied concentration of lactose.

In a consequent next step, we applied the two regio-complementary STs (wild type; P7H-M117A) and also the P7H mutant to the synthesis of 3'- and 6'-sialyllactose from CMP-Neu5Ac and lactose (each 1 mM) (Table 2). Full reaction time courses were

Table 2 Synthesis of sialyllactose and sialyl-*N*-acetylglucosamine using wild-type PdST and mutants thereof.

	WT	P7H	P7H-M117A
Lactose^a			
Yield SL [%]	75	75	72
$R_{6/3SL}$ ^b	≤ 0.006	18	≥ 240
<i>N</i>-acetylglucosamine^a			
Yield SLN [%]	77	83	71
$R_{6/3SLN}$ ^b	≤ 0.006	8	≥ 180

^a 1 mM of acceptor substrate was used. ^b Ratio of 6'- to 3'-sialoside, whereby product identity was verified by NMR. SL, sialyllactose; SLN, sialyl-*N*-acetylglucosamine.

determined (see Fig. S2 in ESI†), and the reported sample composition at each point was carefully verified by a closed mass balance. Using wild-type PdST (see Fig. S2a in ESI†), 3'-sialylation product was obtained in about 75% yield (0.75 mM). The concentration of 6'-sialyllactose never exceeded 0.005 mM. The enzyme's inherent hydrolase activity caused partly non-productive utilization of the CMP-Neu5Ac donor substrate, thus restricting the 3'-sialyllactose yield under the conditions used. Hydrolytic competition was however strongly reduced at elevated lactose concentration (10 mM) where ≥ 95% of the initial CMP-Neu5Ac (1 mM) was utilized for sialyltransfer to acceptor substrate (see Fig. S3 in ESI†). Using the P7H-M117A double mutant, 6'-sialyllactose was synthesized in about 72% yield (0.72 mM) whereas 3'-sialyllactose was present at only ≤ 0.003 mM (see Fig. S2b in ESI†). At the equivalent protein concentration used (0.1 μM), the space-time yield of sialyllactose product was 2.5-fold lower for the reaction of the double mutant as compared to the reaction of wild-type PdST, explained by the different specific ST activities of the two enzymes. Like in wild-type PdST, non-productive (i.e. hydrolytic) utilization of donor substrate by the double mutant was prevented almost completely when lactose was employed in 10-fold molar excess over CMP-Neu5Ac (1 mM) (see Fig. S3 in ESI†). The sialoside product was fully stable up to extended incubation times (180 min) in both enzymatic reactions, demonstrating that minor sialyllactose hydrolase activity of both enzymes (0.1 U mg⁻¹) did not interfere with synthesis under the conditions used. The P7H mutant produced a mixture of regioisomers (Table 2).

Similar results were obtained in synthesis experiments of sialyl-*N*-acetylglucosamine (Table 2; see Fig. S4–S5 in ESI†), which is an important building block towards sialyl-lacto-*N*-neotetraose that is also highly abundant in human milk.^{3,16} Moreover, *N*-acetylglucosamine (LacNAc) sialylation is of high importance as most asialo-HMOs bear LacNAc on their non-reducing end. Product identity of 3'- or 6'- sialyllactose and 3'- or 6'-sialyl-*N*-acetylglucosamine, obtained through wild-type or double mutant catalyzed synthesis, was verified by several methods, including NMR spectroscopy. Overlay of NMR spectra of enzymatic conversions and respective commercial standards (Carbosynth, UK) (HSQC, ¹H; see Fig. S6–S13 in ESI†) unequivocally demonstrated strict α2,3-selectivity of wild-type PdST and strict α2,6-selectivity of the P7H-M117A variant.

To obtain molecular interpretation of the regioselectivity switch achieved in PdST (Tables 1 and 2), we determined the structures of wild-type enzyme, P7H and P7H-M117A in their respective apo-form (X-ray data collection and refinement statistics is shown in the ESI†, Table S2). For a detailed description of crystallization and structure determination see the ESI†. All structures show an open conformation with the same positions of mutated (Pro→His, Met→Ala) and catalytic (Asp¹¹⁴, His²⁸⁴)^{13,15} residues (Fig. 3). The two PdST variants were also co-crystallized in the presence of CMP-Neu5Ac and lactose or 2-nitrophenyl-β-D-galactopyranoside. Additionally, the crystals were soaked with lactose or 2-nitrophenyl-β-D-galactopyranoside.




Fig 3 Close-up views of experimental apo PdST structures. Shown is an overlay of wild-type (grey, PDB code 4V2U) and single P7H mutant (blue, PDB code 4V38) (a) and wild-type (grey, PDB code 4V2U) and double P7H-M117A mutant (orange, PDB code 4V39) (b). Key active site residues (Asp¹¹⁴, His²⁸⁴)^{13,15} and mutation sites (Pro⁷, Pro→His; Met¹¹⁷, Met→Ala) are drawn in sticks.

Unfortunately, only CMP could be clearly placed in the electron density (X-ray data collection and refinement statistics see the ESI†, Table S2, Fig. S14). Note that co-crystallization of *Photobacterium* sp. α2,6-ST (PDB code 2Z4T) with CMP and lactose resulted in a ternary complex.¹⁴ However, overlay of the apo structure of P7H-M117A double mutant (open conformation) with the N- and C-terminal domains of *Photobacterium* sp. α2,6-ST (PDB code 2Z4T, closed conformation)¹⁴ shows almost perfect superimposition of important active site residues for catalytic function (Asp¹¹⁴/Asp²³², His²⁸⁴/His⁴⁰⁵) and regioselectivity (His⁷/His¹²³, Ala¹¹⁷/Ala²³⁵) as well as the Phe³⁴-Lys³⁸ loop (Arg³⁶/Arg¹⁵³) region (see Fig. S15 in ESI†). Our structural observations, taken together with the biochemical characterization, therefore clearly support a highly successful mutational strategy.

Alternative enzymatic α2,3- and α2,6-sialylation of various acceptor substrates, including lactose and sialyl-(poly)-*N*-acetylglucosamine derivatives, was demonstrated before.⁸⁻⁹ What is new here is the use of a *designed pair* of regio-complementary STs

instead of two individual enzymes. The approach of ST engineering might offer a convenient exchange of enzymatic regioselectivity for synthesis of sialyllactose and sialyl-*N*-acetyllactosamine (Table 2).

In conclusion, sequence motifs determining α 2,3- and α 2,6-regioselectivity in β -D-galactoside STs of family GT-80 were identified and exploited through protein engineering of PdST to create a unique pair of regio-complementary STs. Relationships between PdST atomic structure and enzyme selectivity were established. The two STs were applied for α 2,3/ α 2,6-sialylation of lactose and LacNAc from CMP-Neu5Ac.

This work was supported by the Federal Ministry of Economy, Family and Youth (BMWFJ), the Federal Ministry of Traffic, Innovation and Technology (BMVIT), the Styrian Business Promotion Agency, SFG, the Standortagentur Tirol and ZIT-Technology Agency of the City of Vienna through the COMET-Funding Programme managed by the Austrian Research Promotion Agency FFG. We acknowledge the ESRF for the provision of synchrotron-radiation facilities and we would like to thank the ESRF scientific and technical personnel for assistance in using the beam lines ID29 and ID23-2. Parts of this research were carried out at the light source PETRA III at DESY, a member of the Helmholtz Association (HGF).

Notes and references

^a Austrian Centre of Industrial Biotechnology, Petersgasse 14, 8010 Graz, Austria.

^b Institute of Biotechnology and Biochemical Engineering, Graz University of Technology, Petersgasse 12/1, 8010 Graz, Austria.

E-mail: bernd.nidetzky@tugraz.at; Fax: +43 316 8738434; Tel: +43 316 8738400

^c Institute of Molecular Biotechnology Graz, University of Technology, Petersgasse 14, 8010 Graz, Austria.

^d Institute of Molecular Biosciences, University of Graz, Humboldtstrasse 50/3, 8010 Graz, Austria.

^e Institute of Organic Chemistry, Graz University of Technology, Stremayrgasse 9, 8010 Graz, Austria.

† Electronic Supplementary Information (ESI) available: Experimental procedures, sequence alignment, HPAEC-PAD analysis, time-courses of synthesis experiments, ¹H and HSQC NMR spectra, crystallization and structure determination. See DOI: 10.1039/c000000x/

- (a) A. Varki, *Trends Mol. Med.*, 2008, **14**, 351; (b) R. Schauer, *Curr. Opin. Struct. Biol.*, 2009, **19**, 507.
- L. Bode, *Glycobiology*, 2012, **22**, 1147.
- C. Kunz, S. Rudloff, W. Baier, N. Klein and S. Strobel, *Annu. Rev. Nutr.*, 2000, **20**, 699.
- (a) R. M. Hickey, *Int. Dairy J.*, 2012, **22**, 141; (b) M. Marotta, J. T. Ryan and R. M. Hickey, *J. Funct. Foods*, 2014, **6**, 367.
- A. M. Zivkovic and D. Barile, *Adv. Nutr. Int. Rev. J.*, 2011, **2**, 284.
- G.-J. Boons and A. V. Demchenko, *Chem. Rev.*, 2000, **100**, 4539.
- Y. Li and X. Chen, *Appl Microbiol Biotechnol*, 2012, **94**, 887.
- (a) M. Izumi, G.-J. Shen, S. Wacowich-Sgarbi, T. Nakatani, O. Plettenburg and C.-H. Wong, *J. Am. Chem. Soc.*, 2001, **123**, 10909; (b) T. Yamamoto, Y. Hamada, M. Ichikawa, H. Kajiwara, T. Mine, H. Tsukamoto and Y. Takakura, *Glycobiology*, 2007, **17**, 1167; (c) T. Yamamoto, H. Nagae, Y. Kajihara and I. Terada, *Biosci. Biotechnol. Biochem.*, 1998, **62**, 210; (d) T. Yamamoto, M. Nakashizuka, H. Kodama, Y. Kajihara and I. Terada, *J. Biochem.*, 1996, **120**, 104; (e) H. Yu, H. Chokhawala, R. Karpel, H. Yu, B. Wu, J. Zhang, Y. Zhang, Q. Jia and X. Chen, *J. Am. Chem. Soc.*, 2005, **127**, 17618; (f) H. Yu, H. A. Chokhawala, S. Huang and X. Chen, *Nat. Protoc.*, 2006, **1**, 2485; (g) H. Yu, S. Huang, H. Chokhawala, M. Sun, H. Zheng and X. Chen, *Angew. Chem. Int. Ed.*, 2006, **45**, 3938; (h) M. Gilbert, R. Bayer, A.-M. Cunningham, S. DeFrees, Y. Gao, D. C. Watson, N. M. Young and W. W. Wakarchuk, *Nat. Biotech.*, 1998, **16**, 769; (i) O. Blixt, J. Brown, M. J.

- Schur, W. Wakarchuk and J. C. Paulson, *J. Org. Chem.*, 2001, **66**, 2442; (j) D. Vasiliu, N. Razi, Y. Zhang, N. Jacobsen, K. Allin, X. Liu, J. Hoffmann, O. Bohorov and O. Blixt, *Carbohydr. Res.*, 2006, **341**, 1447; (k) M. Gilbert, A.-M. Cunningham, D. C. Watson, A. Martin, J. C. Richards and W. W. Wakarchuk, *Eur. J. Biochem.*, 1997, **249**, 187; (l) T. J. Morley and S. G. Withers, *J. Am. Chem. Soc.*, 2010, **132**, 9430; (m) C. P. C. Chiu, L. L. Lairson, M. Gilbert, W. W. Wakarchuk, S. G. Withers and N. C. J. Strynadka, *Biochemistry*, 2007, **46**, 7196; (n) M. J. Schur, E. Lameignere, N. C. Strynadka and W. W. Wakarchuk, *Glycobiology*, 2012, **22**, 997; (o) X. Chen, V. Thon and H. Yu, *US Pat.* 20140349339, 2014.
- (a) G. F. Herrmann, Y. Ichikawa, C. Wandrey, F. C. A. Gaeta, J. C. Paulson and C.-H. Wong, *Tetrahedron Lett.*, 1993, **34**, 3091; (b) J. Thiem and W. Treder, *Angew. Chem. Int. Ed.*, 1986, **25**, 1096.
 - K. Sujino, R. J. Jackson, N. W. C. Chan, S. Tsuji and M. M. Palcic, *Glycobiology*, 2000, **10**, 313.
 - (a) B. Priem, M. Gilbert, W. W. Wakarchuk, A. Heyraud and E. Samain, *Glycobiology*, 2002, **12**, 235; (b) S. Drouillard, T. Mine, H. Kajiwara, T. Yamamoto and E. Samain, *Carbohydr. Res.*, 2010, **345**, 1394; (c) T. Endo, S. Koizumi, K. Tabata and A. Ozaki, *Appl Microbiol Biotechnol*, 2000, **53**, 257; (d) N. Fierfort and E. Samain, *J. Biotechnol.*, 2008, **134**, 261.
 - (a) K. Schmölzer, D. Ribitsch, T. Czabany, C. Luley-Goedl, D. Kokot, A. Lyskowski, S. Zitzenbacher, H. Schwab and B. Nidetzky, *Glycobiology*, 2013, **23**, 1293; (b) Y. Takakura, H. Tsukamoto and T. Yamamoto, *J. Biochem.*, 2007, **142**, 403; (c) H. Tsukamoto, Y. Takakura, T. Mine and T. Yamamoto, *J. Biochem.*, 2008, **143**, 187; (d) H. Tsukamoto, Y. Takakura and T. Yamamoto, *J. Biol. Chem.*, 2007, **282**, 29794.
 - L. Ni, H. A. Chokhawala, H. Cao, R. Henning, L. Ng, S. Huang, H. Yu, X. Chen and A. J. Fisher, *Biochemistry*, 2007, **46**, 6288.
 - Y. Kakuta, N. Okino, H. Kajiwara, M. Ichikawa, Y. Takakura, M. Ito and T. Yamamoto, *Glycobiology*, 2008, **18**, 66.
 - G. Sugiarto, K. Lau, Y. Li, Z. Khedri, H. Yu, D.-T. Le and X. Chen, *Mol. Biosyst.*, 2011, **7**, 3021.
 - W. Yao, J. Yan, X. Chen, F. Wang and H. Cao, *Carbohydr. Res.* 2015, **401**, 5.